Royalty Report: Drugs, Disease, Pharmaceuticals – Collection: 2437

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Disease
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 2437

License Grant
The licensee is granted rights to the Products used in conjunction with Zonisamide (Zonegram).
Field of Use
Zonegran etc. (Zonisamide) is an antepileptic drug chemically classified as a sulfonamide and unrelated to other anti seizure agents.

IPSCIO Record ID: 2427

License Grant
Pursuant to the Antibody License Agreement dated October 15, 2000, the Company licensing right to the Products to be used in conjunction with RAD (Certican) in a non-U.S. market. Certican-Registered Trademark- (RAD) is a new immunosuppressant being developed for transplantation. The compound currently is in Phase III clinical trials.

IPSCIO Record ID: 26203

License Grant
Licensor grants to Irish Licensee the worldwide, non-transferable sub-licensable, exclusive, license (with the right to make improvements to the LDS Patents) to promote, distribute, market, develop, research, make, have made, use and/or sell any product in the LDS Patents field.
License Property
Products shall mean the following compounds and all complexes, mixtures and other combinations, prodrugs, metabolites, enantiomers, salt forms, racemates, polymorphs and isomers of the following compounds
Metaxalone
Zaleplon (being N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide)
Antegrenâ„¢
Zonisamide
Botulinum Toxin Type B
Ziconotide
Frovatriptan
Tizanidine
Pergolide

Metaxalone is a muscle relaxant used to relax muscles and relieve pain caused by strains, sprains, and other musculoskeletal conditions.
Zaleplon is a sedative-hypnotic, almost entirely used for the management/treatment of insomnia.
Antegren is a humanized monoclonal antibody against the cell adhesion molecule a4-integrin. Natalizumab is used in the treatment of multiple sclerosis and Crohn's disease.
Zonisamide is an antiseizure drug chemically classified as a sulfonamide and unrelated to other antiseizure agents.

Field of Use
Field shall mean any and all uses except  
(a) to the extent required for Elan to comply in all respects with the Orasense Agreements;  
(b) to the extent required for Elan to comply in all respects with the Avlan Agreements;  
(c) to the extent required for Elan to comply in all respects with the GlycoGenesys Licence Agreement;  
(d) to the extent required for Elan to comply in all respects with the Emisphere Settlement Agreement;  
(e) to the extent required for Elan to comply in all respects with the Targeted Genetics Agreements; and  
(f) with respect to any and all Elan Exclusive Products.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.